RxDoctor Payments Data

Carol Drouin

Psychiatric/Mental Health · Nashua, NHNPI 1033208376

Payments from drug & device makers

$701in general payments, 2019–2025

Across 18 payments — averaging $38.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$195
  • Ironshore Pharmaceuticals Inc.$175
  • Otsuka America Pharmaceutical, Inc.$112
  • AbbVie$108
  • Lundbeck LLC$59
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$32
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$701100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$701 in reported general payments places this provider in the 60th percentile of 264 psychiatric/mental health providers in New Hampshire.

See all psychiatric/mental health providers in New Hampshire

Medicare billing

Part B allowed, 2024
$26,665
Medicare patients
61
Services billed
262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl18$22,757
TrintellixVortioxetine Hydrobromide35$16,535
Lisdexamfetamine Dimesylate19$4,758
BelsomraSuvorexant11$4,694
VyvanseLisdexamfetamine Dimesylate12$4,513
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine51$4,419
Duloxetine Hcl140$2,905
Aripiprazole74$2,861
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine58$1,984
Bupropion XlBupropion Hcl103$1,905
Quetiapine Fumarate113$1,802
Clonazepam207$1,768
Escitalopram Oxalate177$1,413
Gabapentin79$1,193
Olanzapine55$1,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$108$22,75718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 264 psychiatric/mental health providers in New Hampshire.

Other psychiatric/mental health in Nashua

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →